---
title: "Analyst Reiterates Buy on Sutro Biopharma, Citing STRO-004 Phase I Readout and Broader ADC Platform Potential"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286482209.md"
description: "TD Cowen analyst Tara Bancroft has reiterated a Buy rating on Sutro Biopharma (STRO) due to the promising Phase I readout for STRO-004 and the potential of its ADC platform. The mid-year readout is seen as crucial, with expectations for a favorable safety profile and efficacy in treating TF-expressing tumors. Bancroft believes this could significantly enhance the drug's commercial prospects beyond cervical cancer. LifeSci Capital also initiated coverage with a Buy rating and a $54 price target."
datetime: "2026-05-14T23:45:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286482209.md)
  - [en](https://longbridge.com/en/news/286482209.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286482209.md)
---

# Analyst Reiterates Buy on Sutro Biopharma, Citing STRO-004 Phase I Readout and Broader ADC Platform Potential

TD Cowen analyst Tara Bancroft has maintained their bullish stance on STRO stock, giving a Buy rating on May 2.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Tara Bancroft has given his Buy rating due to a combination of factors tied to Sutro Biopharma’s emerging ADC pipeline and upcoming clinical catalysts. He views the mid‑year Phase I readout for STRO‑004 as a key event, with early dosing progress suggesting that the company is on track to deliver initial human data that could validate a wider therapeutic window than existing TF‑targeted therapies such as Tivdak.

If STRO‑004 demonstrates a cleaner safety profile with reduced ocular, skin, and bleeding toxicities while showing any degree of activity in heavily pretreated, TF‑expressing tumors, Bancroft believes this would materially expand its commercial potential beyond cervical cancer. He also sees this study as an important test of Sutro’s beta‑glu exatecan linker‑payload platform, which underpins additional assets like STRO‑006 and STRO‑227, and combined with on‑schedule advancement of future ADC programs into 2026, supports a favorable risk‑reward and justifies the Buy recommendation.

In another report released on May 2, LifeSci Capital also initiated coverage with a Buy rating on the stock with a $54.00 price target.

### Related Stocks

- [STRO.US](https://longbridge.com/en/quote/STRO.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [LABD.US](https://longbridge.com/en/quote/LABD.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)

## Related News & Research

- [Sutro Biopharma: Buy Rating on Strong ADC Execution, Cash Runway Into 2028, and Multiple 2026 Catalysts](https://longbridge.com/en/news/286599325.md)
- [Sutro Biopharma Q1 revenue beats analyst expectations](https://longbridge.com/en/news/286462966.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Relay drug shows early promise against rare blood vessel diseases](https://longbridge.com/en/news/287094432.md)